Risdorfer v. Ascentage Pharma Group Inc.

CourtDistrict Court, D. Maryland
DecidedJuly 19, 2023
Docket1:23-cv-00987
StatusUnknown

This text of Risdorfer v. Ascentage Pharma Group Inc. (Risdorfer v. Ascentage Pharma Group Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Risdorfer v. Ascentage Pharma Group Inc., (D. Md. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

ALBERT RISDORFER,

Plaintiff,

v. Civil Action No. ELH-23-987 ASCENTAGE PHARMA GROUP INC., Defendant. MEMORANDUM OPINION Plaintiff Albert Risdorfer filed suit in State court against his former employer, Ascentage Pharma Group, Inc. (“Ascentage”). See ECF 5 (the “Complaint”).1 In Count I, titled “Retaliation,” plaintiff alleges a claim of unlawful retaliation, pursuant to “Section 27-19 of the Montgomery County, Maryland Human Rights Ordinance (‘MCHRO’)”; Md. Code (2021 Repl. Vol., 2022 Supp.), § 20-1202 of the State Government Article (“S.G.”); and Maryland common law. Id. at 1. Count II is titled “Wrongful Termination in Violation of Public Policy.” Id. at 9. According to plaintiff, he engaged in protected activity when he disclosed to defendant that its hiring practices were discriminatory, and defendant retaliated by terminating his employment on January 14, 2022. Further, plaintiff maintains that his termination “violated a clear mandate of public policy because Risdorfer was terminated for reporting . . . his concerns regarding Ascentage’s failure to comply with ERISA . . . .” ECF 5, ¶ 49(v). Plaintiff seeks, inter alia, compensatory and punitive damages, attorney’s fees, and costs. ECF 5.

1 The Complaint does not contain a comma in the defendant’s name. However, defendant uses a comma in its submissions. See, e.g., ECF 1. Suit was initially filed in the Circuit Court for Montgomery County, Maryland. ECF 1-2. Ascentage, a Delaware corporation “headquartered” in Maryland, ECF 5, ¶ 2, timely removed the case to federal court, based on federal question jurisdiction under 28 U.S.C. § 1331. ECF 1 (“Notice of Removal”). In particular, defendant contends that plaintiff’s claims are based on

alleged violations of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), 29 U.S.C. §1001 et seq.; see also ECF 7. Ascentage has moved to dismiss the suit, pursuant to Fed. R. Civ. P. 12(b)(6). ECF 7. The motion is supported by a memorandum. ECF 7-1 (collectively, the “Motion to Dismiss”). Plaintiff opposes the Motion to Dismiss. ECF 10. Ascentage replied. ECF 14. Risdorfer filed a motion to remand (ECF 13), supported by a memorandum. ECF 13-1 (collectively, the “Motion to Remand”). Ascentage opposes the Motion to Remand. ECF 15. Risdorfer replied. ECF 16. No hearing is necessary to resolve the motions. See Local Rule 105.6. For the reasons that follow, I shall grant the Motion to Remand and deny the Motion to Dismiss, without prejudice to

defendant’s right to renew the motion in State court. I. Factual and Procedural Background2 Ascentage is a Delaware corporation with its headquarters in Rockville, Maryland. ECF 5, ¶ 2. It is the U.S. subsidiary of Ascentage Pharma Group International (“Ascentage International”), a Chinese multinational corporation. Id. ¶ 10.

2 At this juncture I must assume the truth of the facts alleged in the suit. See Fusaro v. Cogan, 930 F.3d 241, 248 (4th Cir. 2019). Throughout the Memorandum Opinion, the Court cites to the electronic pagination. However, the electronic pagination does not always correspond to the page number imprinted on a particular submission. On or about December 1, 2021, Ascentage hired Risdorfer to serve as the company’s senior director of human resources (“HR”). ECF 5, ¶ 9. As part of plaintiff’s employment offer, Risdorfer was awarded a signing bonus. But, the bonus was subject to repayment if plaintiff’s employment were to end within a year, unless he was laid off or his position was eliminated. Id. ¶ 9.

Jim Tripp, Ascentage’s vice president of U.S. operations, told Risdorfer that he was hired to “drive much needed changes” in the company’s HR department. Id. ¶ 11. Tripp intended to replace Jason Gilmore, who was then Ascentage’s director of HR. Id. ¶ 13. Risdorfer’s “second- line supervisor” was Dajun Yang, CEO of Ascentage. Id. ¶ 12.3 Yang lived in China, but also visited Ascentage’s office in Maryland on a frequent basis. Id. In addition, Yang served as Tripp’s direct supervisor. Id. Upon commencing employment, Risdorfer learned that Gilmore was still employed by Ascentage. Id. ¶ 14. And, Risdorfer learned from Tripp that he (Risdorfer) would have to terminate Gilmore, one of the few African American men at Ascentage. Id. ¶¶ 14, 23. Risdorfer told Tripp that he needed to learn about the company’s human resource processes, which were not well

documented. Id. ¶ 15. Risdorfer also told Tripp that he would wait to terminate Gilmore until he familiarized himself with Ascentage’s HR processes. Id. Soon after plaintiff’s employment began, he “determined that Ascentage’s human resources functions were dysfunctional and error prone.” Id. ¶ 16. And, Gilmore informed Risdorfer that “some of Ascentage’s practices may have been also unlawful.” Id. For example, Gilmore informed Risdorfer that Ascentage “ordered” Gilmore to provide the Chinese parent company with employees’ personal health information, in violation of the

3 The Complaint does not indicate whether Yang was the CEO of Ascentage or Ascentage International. Health Insurance Portability and Accountability Act, and also with employees’ social security numbers. ECF 5, ¶¶ 17, 18. Gilmore’s refusal to send the information was met with “animosity” from Ascentage’s parent company. Id. ¶ 18. Gilmore also learned that Ascentage was “improperly handling” the tax “obligations” of U.S. citizens working in China. Id. ¶ 19. He attempted to

investigate these issues, but Tripp prevented him from doing so, and told Gilmore that it was “‘none of his business.’” Id. ¶ 20. Moreover, Risdorfer “independently” discovered that “several of Ascentage’s tax and employment practices were possibly unlawful.” Id. ¶ 21. Risdorfer reported his concerns to Tripp in December 2021, and indicated that Tripp “needed to investigate” the issues. Id. ¶ 22. But, Tripp “told Risdorder ‘not to worry about it’” and thus Risdorfer was unable to investigate further. Id. Also in December 2021, Risdorfer determined that terminating Gilmore would place Ascentage “at risk of a lawsuit,” as Gilmore’s “internal reports of possible” illegal activity were protected activity under federal and state law. Id. ¶ 23. Further, plaintiff “realized” that because Gilmore was “one of the few African American men at Ascentage,” firing him could lead to a race

discrimination claim. Id. At about the same time, Risdorfer told Tripp that Ascentage was “hiring a disproportionate number of Chinese managers,” placing the company at risk of claims of racial bias and employment discrimination. Id. ¶ 28. But, “Tripp dismissed Risdorfer’s concerns and warnings.” Id. During the same time frame, Risdorfer proposed filling an HR manager vacancy with an experienced HR professional, known to Risdorfer, who was not Chinese. Id. ¶ 29. But, Yang and Ascentage’s head of finance, Lei Elaine Zhi, opted to hire a less qualified employee with no HR experience “who was Chinese and apparently connected to one of Yang’s friends.” Id. A few days before December 25, 2021, Risdorfer met with Yang to provide an update as to his “progress” in reforming Ascentage’s HR “functions.” ECF 5, ¶ 24. Yang was mainly concerned about Risdorfer’s “progress in firing Gilmore,” and Risdorfer shared his reservations in connection with the proposed termination. Id. ¶ 25. In mid January of 2022, Risdorfer suggested to Tripp that, in lieu of termination, Gilmore

should instead be demoted in exchange for a waiver of potential claims. Id. ¶ 26.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Strawbridge v. Curtiss
7 U.S. 267 (Supreme Court, 1806)
Shamrock Oil & Gas Corp. v. Sheets
313 U.S. 100 (Supreme Court, 1941)
Verlinden B. v. v. Central Bank of Nigeria
461 U.S. 480 (Supreme Court, 1983)
Shaw v. Delta Air Lines, Inc.
463 U.S. 85 (Supreme Court, 1983)
Metropolitan Life Insurance v. Massachusetts
471 U.S. 724 (Supreme Court, 1985)
Pilot Life Insurance v. Dedeaux
481 U.S. 41 (Supreme Court, 1987)
Metropolitan Life Insurance v. Taylor
481 U.S. 58 (Supreme Court, 1987)
Caterpillar Inc. v. Williams
482 U.S. 386 (Supreme Court, 1987)
Christianson v. Colt Industries Operating Corp.
486 U.S. 800 (Supreme Court, 1988)
English v. General Electric Co.
496 U.S. 72 (Supreme Court, 1990)
Ingersoll-Rand Co. v. McClendon
498 U.S. 133 (Supreme Court, 1990)
Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
Crosby v. National Foreign Trade Council
530 U.S. 363 (Supreme Court, 2000)
Beneficial National Bank v. Anderson
539 U.S. 1 (Supreme Court, 2003)
Aetna Health Inc. v. Davila
542 U.S. 200 (Supreme Court, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
Risdorfer v. Ascentage Pharma Group Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/risdorfer-v-ascentage-pharma-group-inc-mdd-2023.